The development of rCHO cell lines that stably express therapeutic proteins is crucial for pharmaceutical protein industrial production. In this study, a systematic method was established to identify genomic hotspots for exogenous protein expression in CHO cells and construct stable recombinant CHO cell strains. Four stable monoclonal cell lines (1b7, 1d2, 2d9, and 2f7) were obtained by using the lentiviral random integration reporter gene. Chromosome mapping analysis found four stable integration sites: chr1₀ (7, 30, 83, 299-7, 32, 45, 508 bp) in 1b7, chr1₀ (17, 69, 68, 187-17, 69, 68, 191 bp) in 1d2, chr3 (4, 08, 81, 262-4, 08, 99, 858 bp) in 2d9, and chr5 (1, 69, 77, 575-1, 70, 61, 744 bp) in 2f7. Based on these sites, we developed recombinant CHO cells capable of long-term stable expression of foreign proteins through the combined application of CRISPR/Cas9 technology and Bxb1 recombinase-mediated cassette exchange. Utilizing "promoter capture technology", all screened LP cell monoclonal lines can express exogenous proteins, with the entire construction process completed in just 2∼3 weeks.
Ding et al. (Wed,) studied this question.